Dermatose neutrophilique aiguë induite par le bortezomib

Introduction. - Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological, and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. Case Report. - We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. Discussion. - The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence. (C) 2009 Elsevier Masson SAS. All rights reserved.